Christopher Codeanne, Advisory Board
Mr. Codeanne is a multi-faceted, results-oriented executive with significant leadership, board, operational and transaction-related experience (buy and sell side) and a proven track record of organizing and mobilizing teams to strategically focus and develop businesses, penetrate new markets, increase profit margins and improve stakeholder returns. Mr. Codeanne has an advanced degree with extensive domestic and international experience in general business and operations management, financial operations, business analysis, corporate governance and reporting for publicly traded and venture/private equity backed organizations.
Mr. Codeanne was a member of the Board of Directors, Audit Committee Chairman, and member of Nominating Committee of Cornerstone Therapeutics Inc. (NASDAQ: CRTX)(now Chiesi USA), a specialty pharmaceutical company from October 2008 through January 2014. Mr. Codeanne previously served as a member of the Compensation Committee for a four-year period and was a member of the Special Committee charged with evaluating and consummating the ultimate sale of the business to Chiesi Farmaceutici in January 2014.
Mr. Codeanne was most recently the Chief Financial Officer (“CFO”) of Oxford Performance Materials, a recognized leader in advanced materials science that develops proprietary material, process and application technologies and applies high performance additive manufacturing (HPAM™) to produce fully functional end-use structural parts for the aerospace, industrial, and biomedical industries. Mr. Codeanne was instrumental in the sale of the aerospace assets to Hexcel Corporation.
Prior to Oxford Performance Materials, Mr. Codeanne was the Chief Operating Officer (“COO”) and CFO of Premier Research, an international professional services organization with over 1,000 employees providing clinical development services to the pharmaceutical, biotechnology and medical device industries. Mr. Codeanne was instrumental in turning around the company’s operational and financial performance and converting substantial operating losses into operating income over a three-year period. Mr. Codeanne also served as a member of the Board of Directors of Premier Research.
Prior to Premier Research, Mr. Codeanne was the COO and CFO of Oncopartners, a venture backed, specialized international oncology contract research organization. Mr. Codeanne was responsible for all day to day operations including oversight of clinical operations, business development, and finance and administration as well as identification, oversight and execution of strategic growth initiatives. Mr. Codeanne served as the CFO of Averion International Corp., a publically traded international contract research organization, (“Averion”) from December 2006 through April 2008 where he was responsible for all treasury, finance, mergers and acquisition, accounting, SEC reporting, human resources, information technology, contract and proposals, legal, and risk management functions. As CFO of Averion International, he doubled the company’s size through the financing, acquisition and integration of a European-based CRO. Prior to being appointed as CFO of Averion, from 2002 through July 2006, Mr. Codeanne was the CFO of SCIREX Corporation LLC (“SCIREX”), where he was responsible for all finance, treasury, accounting, human resources, information technology, risk management and facilities management functions. At SCIREX Corporation, he was a key member of the leadership team that grew the business from under $10MM in revenue to over $150MM. Mr. Codeanne led the sale of SCIREX to Premier Research in 2006.
Mr. Codeanne obtained an MBA from the University of Connecticut with a concentration in finance and a Bachelor of Science degree in Accounting from Fairfield University. Mr. Codeanne is a member of the American Institute of Certified Public Accountants.